About: SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS
Creator	Fumagalli, Roberto Puoti, Massimo Tarsia, Paolo Baiguera, Chiara Basile, Andriano Bellone, Andrea Bottiroli, Maurizio Colombo, Fabrizio Corradin, Matteo Epis, Oscar It, Roberto Massimiliano Epis, Oscar Merli, Marco Mondino, Michele Moreno, Mauro Pastori, Stefano Perno, Carlo Rossotti, Roberto Ruggeri, Ruggero Travi, Giovanna Ughi, Nicola
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: As the novel SARS-CoV-2 pandemic occurred, no specific treatment was yet available. Inflammatory response secondary to viral infection might be the driver of severe diseases. We report the safety and efficacy (in terms of overall survival and hospital discharge) of the anti-IL6 tocilizumab (TCZ) in subjects with COVID-19. METHODS: This retrospective, single-center analysis included all the patients consecutively admitted to our Hospital with severe or critical COVID-19 who started TCZ treatment from March 13th to April 03rd, 2020. A 1:2 matching to patients not treated with TCZ was performed according to age, sex, severity of disease, P/F, Charlson Comorbidity Index and length of time between symptoms onset and hospital admittance. Descriptive statistics and non-parametric tests to compare the groups were applied. Kaplan Meier probability curves and Cox regression models for survival, hospital discharge and orotracheal intubation were used. RESULTS: Seventy-four patients treated with TCZ were matched with 148 matched controls. They were mainly males (81.5%), Caucasian (82.0%) and with a median age of 59 years. The majority (69.8%) showed critical stage COVID-19 disease. TCZ use was associated with a better overall survival (HR 0.499 [95% CI 0.262–0.952], p=0.035) compared to controls but with a longer hospital stay (HR 1.658 [95% CI 1.088–2.524], p=0.019) mainly due to biochemical, respiratory and infectious adverse events. DISCUSSION: TCZ use resulted potentially effective on COVID-19 in terms of overall survival. Caution is warranted given the potential occurrence of adverse events. FINANCIAL SUPPORT: Some of the tocilizumab doses used in the subjects included in this analysis were provided by the “Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia” (EudraCT Number: 2020–001110–38) supported by the Italian National Agency for Drugs (AIFA). No specific funding support was planned for study design, data collection and analysis and manuscript writing of this paper.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2020.07.008
bibo:pmid	32652164
has license	no-cc
sha1sum (hex)	98a9e37d7f86b3340859c360ee8a041261075b07
schema:url	https://doi.org/10.1016/j.jinf.2020.07.008
resource representing a document's title	SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS
has PubMed Central identifier	PMC7345400
has PubMed identifier	32652164
schema:publication	J Infect
resource representing a document's body	covid:98a9e37d7f86b3340859c360ee8a041261075b07#body_text
is schema:about of	named entity 'care' named entity 'function' named entity 'USE' named entity 'severe' named entity 'COMPLICATIONS' named entity 'pathogenesis' named entity 'Cytokine release syndrome' named entity 'Tocilizumab' named entity 'IL6' named entity 'CORONAVIRUS' named entity 'COVID' named entity 'evolution' named entity 'fever' named entity 'Pearson correlation coefficient' named entity 'randomized clinical trial' named entity 'gram-positive bacteria' named entity 'candidemia' named entity 'homeostasis' named entity 'North Africa' named entity 'respiratory failure' named entity 'respiratory conditions' named entity 'ritonavir' named entity 'ICU' named entity 'Interleukin-6' named entity 'critically ill' named entity 'ANOVA' named entity 'epidural abscess' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'plasma' named entity 'compassionate use program' named entity 'pathogenesis' named entity 'inflammatory' named entity 'severe diseases' named entity 'cytokine' named entity 'Italy' named entity 'liver enzyme elevation' named entity 'drug administration' named entity 'lopinavir' named entity 'interleukin' named entity 'thrombotic complications' named entity 'MENA' named entity 'respiratory distress' named entity 'respiratory rate' named entity 'comparison group' named entity 'severe infections' named entity 'oxygen pressure' named entity 'COVID' named entity 'inflammatory mediators' named entity 'protein' named entity 'IL-6' named entity 'interleukin-1 receptor' named entity 'neutrophils' named entity 'platelets' named entity 'clinical features' named entity 'lung compliance' named entity 'rheumatologic' named entity 'inflammatory markers' named entity 'rheumatological' named entity 'single center' named entity 'inflammatory state'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software